News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Julia Libunao

Advertisement

Julia Libunao is a lead consultant, strategy and program leadership, for Halloran Consulting Group.

Articles by Julia Libunao

Why Program Management is the Key to Success for Life Science Companies

ByCarolina Ahrendt,Pam Wilson,Julia Libunao
February 6th 2023

Delivering value with enterprise program management.

Advertisement

Latest Updated Articles

  • Why Program Management is the Key to Success for Life Science Companies
    Why Program Management is the Key to Success for Life Science Companies

    Published: February 6th 2023 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Bristol Myers Squibb Enters $1.5 Billion Definitive Agreement Acquiring Orbital Therapeutics

2

Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform

3

FDA Approves Libtayo for Immunotherapy for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma

4

Novo Nordisk Enters $4.7 Billion Definitive Agreement with Akero Therapeutics

5

The Situation We Faced: The Development and Commercialization of MariTide

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us